Furthermore, we demonstrate TP5’s synergistic efficacy as an adjuvant for adoptive T cell therapies, providing a novel immunomodulatory strategy to amplify therapeutic responses and overcome current limitations in cancer immunotherapy. Here, TMPO is linked to cancer.